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Oral lesions are among the early signs of HIV infection and can predict its progression to acquired immunodeficiency syndrome 
(AIDS). A better understanding of the oral manifestations of AIDS in both adults and children has implications for all health care 
professionals. The knowledge of such alterations would allow for early recognition of HIV-infected patients. The present paper 
reviews epidemiology, relevant aspects of HIV infection related to the mouth in both adults and children, as well as current trends 
in antiretroviral therapy and its connection with orofacial manifestations related to AIDS.
KEYWORDS: HIV; AIDS; Oral diseases; Oral manifestations; Mouth.
EPIDEMIOLOGY OF HIV INFECTION AND ITS 
CURRENT TRENDS
HIV infection remains a significant health care problem.1 
Since Barre-Sonoussi and Gallo’s initial description of the 
human immunodeficiency virus type I (HIV-1) in 1983 and 
Clavel et al. first described HIV-2 in 1986, these two viruses 
have been recognized for almost 20 years as the primary cause 
of the acquired immunodeficiency syndrome (AIDS).2
By the end of 2005, an estimated 40.3 million people 
were alive with HIV infection in the world, the vast majority 
of whom were resident in low-income countries.3 However, 
in 2007, advances in the methodology of estimating HIV 
epidemics applied to an expanded range of country data, 
resulting in substantial changes to the estimates of the 
number of persons living with HIV worldwide; nevertheless, 
the qualitative interpretation of the severity and implications 
of the pandemic have altered little.4 The estimated number of 
persons living with HIV worldwide in 2007 is now assumed 
to be 33.2 million [30.6–36.1 million], a reduction of 16% 
compared with the estimate published in 2006 (39.5 million 
[34.7–47.1 million]).4 Of this number, only 1.6 million 
live in high-income countries; the remaining more than 
95% of HIV-infected people live in developing countries.5 
In developed countries, the number of children newly 
infected with HIV has decreased dramatically. However, 
in developing countries, there are an estimated 3.5 million 
children younger than the age of 15 who are infected. In 
developing countries in 2007, an estimated 330,000 children 
younger than the 15 years of age died of AIDS, and more 
children younger than the age of 5 years die from AIDS now 
than from any other cause.6
The prevalence and incidence of HIV/AIDS vary 
considerably from continent to continent, from country to 
country, and from region to region. Several countries in 
sub-Saharan Africa report infection rates of 30%, especially 
in urban areas; however, in other countries, HIV prevalence 
still remains low. Low national prevalence rates can be 
misleading. They often disguise serious epidemics that are 
initially concentrated in certain localities or among specific 
population groups and that threaten to spill over into the 
wider population.7
HIV infection leading to AIDS has been a major cause 
of illness and death among children, teens, and young adults 
worldwide. AIDS has been the sixth leading cause of death 
in the United States among 15- to 24-year-olds since 1991. 
In recent years, AIDS infection rates have been increasing 
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rapidly among teens and young adults. Half of all new HIV 
infections in the United States occur in people under 25; 
thousands of teens acquire new HIV infections each year.8 
In 2007 alone, 420,000 infants and children were newly 
infected with HIV in developing countries, more than 1,150 
every day. An estimated 330,000 children died from HIV 
and AIDS during 2007, joining more than 4 million children 
already claimed by the epidemic. 6
There are several ways in which someone can become 
infected with HIV, and some of these transmission routes 
are well defined. HIV infection can be transmitted through 
unprotected sexual intercourse with an infected partner The 
HIV virus can be transmitted through unprotected oral sex, 
both from fellatio and cunnilingus, although the precise 
degree of risk of disease transmission to and from the mouth 
is difficult to establish as these practices often take place along 
with insertive sexual intercourse.9 Injection or transfusion 
of contaminated blood or blood products (infection through 
artificial insemination, skin grafts, and organ transplants is 
also possible),10 sharing unsterilized injection equipment that 
was previously used by an infected person,11 and maternal-
fetal transmission (during pregnancy, at birth, and through 
breastfeeding)12,13 are other transmission routes.
Occupational HIV infections of healthcare or laboratory 
workers may occur, but this mode of infection is not 
frequent.14 Transmission of HIV from an infected patient to 
a health-care worker has been documented after parenteral 
or mucous-membrane exposure to blood. However, this risk 
is less than 1%, is limited to exposure to blood, and can be 
further minimized through the availability of more effective 
antiretroviral therapy (ART).15
There remains little evidence that HIV is transmitted via 
oral fluids.16 However, saliva seems to play an important role 
in an individual’s protection from HIV infections. The saliva of 
non-HIV-infected persons contains non-immune endogenous 
inhibitors of HIV such as mucins, defensins, thrombospondin, 
and various salivary proteins, in particular the secretory 
leukocyte protease inhibitor.17 There is also evidence that 
the hypotonicity of saliva itself exerts a significant inhibitory 
effect on cell-associated HIV replication.18
The risk of transmission of HIV from a patient to a dental 
health care worker remains very low, if not infinitesimal.19 
Transmission of HIV from an infected dental health care 
worker is also rare, although possible.20 Nevertheless, dental 
health care workers are at risk of nosocomial acquisition 
of HIV and other blood-borne viruses (BBVs), and these 
individuals should be aware of, and follow available national 
guidelines on occupational exposure to BBVs.21
As in other virus infections, the individual course of HIV 
infection depends on both host and viral factors; however, 
the factors that may predispose one to or promote the 
development of the AIDS syndrome are largely unknown.23 
The clinical course of AIDS described in the following 
sentences refers to HIV infection in the absence of highly 
active antiretroviral therapy (HAART). Several factors, 
including immunological and virological variables, have 
been reported to predict disease progression.24 The acute 
viral syndrome of primary HIV infection (which is defined 
as the time period from initial infection with HIV to the 
development of an antibody response) shows symptoms that 
often resemble those of mononucleosis.25 These symptoms 
appear within days to weeks of exposure to HIV. However, 
clinical signs and symptoms may not occur in all patients.26
After the acute infection, equilibrium between viral 
replication and the host immune response is usually 
reached, and many infected individuals may have no clinical 
manifestations of HIV infection for years. Even in the 
absence of antiretroviral treatment, this period of clinical 
latency may last 8-10 years or more.27 However, the term 
“latency period” may be misleading, given the incredibly 
high turnover of the virus and the relentless daily destruction 
of CD4+ T-cells.28 At the end of the latency period, a number 
of symptoms or illnesses may appear that do not fulfill 
the definition of AIDS. These symptoms include slight 
immunological, dermatological, hematological, neurological, 
and orofacial signs.29
Oral manifestations are among the earliest and most 
important indicators of HIV infection.30 At present, three 
groups of oral manifestations of AIDS are defined based 
on their intensity and features. Group 1 is composed of 
seven cardinal lesions (oral candidosis, hairy leukoplakia, 
Kaposi sarcoma, linear gingival erythema, necrotizing 
ulcerative gingivitis, necrotizing ulcerative periodontitis, 
and non-Hodgkin lymphoma) that are strongly associated 
with HIV infection.31 The second group includes atypical 
ulcers, salivary glands diseases, viral infection such as 
cytomegalovírus (CMV), herpes simplex virus (HSV), 
papillomavirus (HPV), and herpes zoster virus (HZV). On 
group 3 are lesion rarer than those on groups 1 and 2, such 
as diffuse osteomyelitis and squamous cell carcinoma.32 
The presence of oral lesions can have a significant impact 
on health-related quality of life. Oral health is strongly 
associated with physical and mental health, and there are 
significant increases in oral health needs in people with HIV 
infection, especially in children, and in adults particularly 
in relation to periodontal diseases. Thus, physical and 
mental health measures of HIV patients should incorporate 
indicators of oral functioning and well-being. Data obtained 
in the Coutler et al. study have shown that a one-point 
increase in oral health was associated with a 0.05 (p < 0.000) 
increase in mental health and a 0.02 increase in physical 
health (p = 0.031).33
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ADVANCEMENT IN THE TREATMENT OF HIV 
DISEASE
Significant advancement has been made in the treatment 
of HIV disease. This progress has contributed to a decrease 
in AIDS-related deaths and, consequently, has increased 
the number of individuals living with HIV throughout the 
world.34 The treatment of HIV is directed principally towards 
the specific inhibition of HIV replication (antiretroviral 
therapy) and the prevention and management of opportunistic 
infections and malignancies;35 therefore, the ultimate goal of 
antiretroviral therapy should always be borne in mind: to 
prolong the patient’s life while maintaining the best possible 
quality of health and life.36
Antiretroviral drugs (ARDs) now comprise four classes 
of agents: nucleoside analog reverse transcriptase inhibitors 
(NRTIs), non-nucleoside analog reverse transcriptase 
inhibitors (NNRTIs), protease inhibitors (PIs), and entry 
inhibitors.37 This last class of drug blocks HIV entry 
into host cells and has only become clinically available 
recently; these drugs include attachment inhibitors, co-
receptor inhibitors, and fusion inhibitors, and they are 
usually reserved for treating HIV-1 infection in treatment-
experienced patients.38
Combination therapy, using three or more drugs (usually, 
but not always, two NRTIs and either a PI or NNRTI) 
reduces HIV viremia to below detectable levels.39 Such 
combination therapy, known better as antiretroviral therapy 
(ART) or highly active antiretroviral therapy (HAART), has 
greatly improved the prognosis for persons infected with 
HIV. However, as with almost all antimicrobials, in vivo 
resistance to NRTIs, NNRTIs, and PIs has been documented 
as well as transmission of antiretroviral resistant strains 
of HIV.40 In addition, the various ARDs can give rise to 
a wide spectrum of orofacial adverse reactions, such as 
erythema multiforme, hyperpigmentation, ulcers, cheilitis, 
lipodystrophy syndrome, and so on; the relationships of 
these reactions to the drugs used are summarized in Table 1. 
HIV-associated lipodystrophy syndrome is considered to be 
one of the most clinically relevant adverse effects of ART.41 
This syndrome is characterized by a generalized loss of fatty 
tissue.42 The nasolabial regions and temples are the most 
common sites of facial involvement, although orbital fat can 
also be lost when fatty tissue loss is severe. Fat wasting in the 
limbs leads to prominence of the subcutaneous veins while 
that of the face and buttocks leads to marked hollowing and 
wrinkling of the skin.43 Effective ARTs are rarely available 
to HIV-infected persons in the developing world, particularly 
in areas of Africa. In some countries that have no specific 
HIV therapy, the treatment of HIV disease is still principally 
directed toward the elimination of opportunistic infections, 
and even this treatment is often unavailable.44 In the absence 
of specific HIV therapy, health care resources are being 
increasingly utilized but with little survival benefit for the 
individual. Resources available for treating patients vary 
considerably between the richer and poorer countries of the 
continent.45 For example fluconazole only recently became 
widely available in South Africa, and even topical antiseptic 
agents, such as gentian violet which are used in Uganda to 
treat trigeminal zoster infections, are of limited availability. 
Extracts of traditionally used East African medicinal plants 
(e.g., Entada abyssinica, Terminalia spinosa, Harrisonia 
abyssinica, Ximenia caffra, Azadirachta indica, and Zahna 
Africana) that have in vitro antifungal actions have been 
advocated as possible therapeutic alternatives to more 
expensive antifungal agents.46 Likewise, 0.5% lawsone 
methyl ether preparations with in vitro antifungal activity 
similar to that of chlorhexidine gluconate and 1.0% 
Table 1 - Oral and systemic side effects of antiretroviral 
drugs (ARDs)
Oral side effect Class of drug Name of drug
Erythema multiforme NRTIs Zidovudine (ZVD)
Abacavir (ABC)
Didanosine (DDI)
Zalcitabine
NNRTIs Efavirenz 
Delaviridine
Nevirapine 
Saquinavir
Hyperpigmentation NRTIs Zidovudine (ZVD)
Lipodystrophy NRTIs Stavudine
PIs Saquinavir
Ritonavir
Xerostomia NRTIs Lamivudine (3TC)
Didanosine
PIs Saquinavir
Indinavir
Nelfinavir
Ritonavir
Parotid lipomatosis PIs Indinavir 
Ritonavir
Saquinavir
Nelfinavir
Amprenavir
Cheilitis PI Indinavir
Perioral paresthesia PIs Ritonavir
Amprenavir
Taste disturbances PIs Indinabir
Ritonavir
Facial edema PIs Ritonavir
Ulcers NRTIs Abacavir 
Zalcitabine 
Nevirapine 
Lip enlargement EIs Enfuvirtide
NRTI = nucleoside analog reverse transcriptase inhibitors; NNRTI = non-
nucleoside analog reverse transcriptase inhibitors; PIs = protease inhibitors; 
EI = entry inhibitors
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clotrimazole cream have been suggested for the treatment of 
candidal infections in the developing world.47
Antiretroviral therapy is very effective at suppressing 
viral replication. However, viral rebound with resistance 
does occur, primarily due to sub-optimal compliance and 
drug toxicities. It is during the period of failing HAART 
when the HIV load may well be high or rising that the 
transmission of drug-resistant HIV to susceptible individuals 
occurs.48 The aforementioned trends in anti-HIV therapy are 
of relevance to general dental practice. People living with 
HIV infection may complain of, or have, orofacial features 
of ART. In contrast, HIV-infected individuals taking ART 
are likely to have the well-recognized, common orofacial 
features of untreated HIV disease or may develop others oral 
manifestations related to ART.49
CURRENT ASPECTS OF THE ORAL MANIFESTA-
TIONS OF AIDS
Since the advent of HAART, clinical and epidemiological 
observations have shown a considerable decline in the 
mortality and morbidity of HIV-positive patients, which can 
be attributed to a reduction of HIV viral load and the recovery 
of immune function in previously ill subjects.50 Patients are 
protected to some extent against several oral lesion, i.e., 
candidosis, salivary gland disease, sarcoma, Kaposi’s sarcoma, 
and oral hairy leukoplakia.51 The prevalence of all oral lesions 
has decreased by more than 30% since the introduction of 
HAART. 52 For example, in a study conducted by Tukutuku 
et al.53
,
 the prevalence of necrotizing ulcerative gingivitis 
(NUG) and periodontitis (NUP) before HAART was 17%, 
and 16% of all lesions included these bacterial infections; 
nowadays the rates are lower at 10% for NUG and 5% for 
NUP.54 However, the prevalence of some oral lesions has 
nevertheless increased, such as HIV salivary gland disease, or 
remained the same, such as oral candidosis, aphtous ulcers, 
and Kaposi’s sarcoma.55
The oral manifestations of AIDS in adults (Table 2) and 
children (Table 3) were classified before the advent of ART 
by EC-Clearinghouse.56-58 Although the EC-Clearinghouse 
classification was developed over a decade ago, there have 
been few new infections recognized in HIV-infected persons, 
Table 2 - Classification of the oral manifestations of HIV disease in adults
Group 1
lesions strongly associated with 
HIV infection
Group 2
lesions less commonly associated with HIV infection
Group 3
lesions seen in HIV infection
Candidosis
• Erythematous
• Pseudomembranous
Bacterial infections
• Mycobacterium avium-intracellulare
• Mycobacterium tuberculosis
Bacterial infections
• Actinomyces israelii
• Escherichia coli
• Klebsiella pneumonia
Hairy leukoplakia Melanotic hyperpigmentation Cat-scratch disease
Kaposi’s sarcoma Necrotizing (ulcerative) stomatitis (Figure 5) Drug-reactions
• Ulcerative
• erythema multiforme
• lichenoid
• toxic epidermolysis
Non-Hodgkin’s lymphoma Salivary gland diseases
• Dry mouth due to decreased salivary flow rate
• Unilateral or bilateral swelling of major salivary glands
Epithelioid (bacillary) angiomatosis
Periodontal disease
• Linear gingival erythema
• Necrotizing gingivitis 
• Necrotizing periodontitis
Thrombocytopenic purpura Fungal infections other than candida
• Cryptococcus neoformans
• Geotrichum candidum
• Histoplasma capsulatum
• Mucoraceae (mucormycosis, zygomycosis)
• Aspergillus flavus
Ulceration NOS (not otherwise specified) Neurological disturbances
• Facial palsy
• Trigeminal neuralgia
Viral infections
• Herpes simplex virus
• Human papillomavirus lesions
   ♦ Condyloma acuminatum
   ♦ Focal epithelial hyperplasia
   ♦ Verruca vulgaris
• Varicella zoster virus
   ♦ Herpes zoster
   ♦ Varicella
Viral infections 
• Cytomegalovirus
• Molluscum contagiosum
463
CLINICS 2009;64(5):459-70 Oral complications of HIV disease
Leão JC et al.
perhaps reflecting the wide availability of HAART in the 
developed world.1 
The frequency and presentation of some oral lesions 
associated with HIV infection will, and do, vary with the 
geography. Patients who do not receive ART are likely to still 
have the common oral features of HIV disease: candidosis 
(typically acute pseudomembranous candidosis), hairy 
leukoplakia, Kaposi’s sarcoma, and perhaps periodontal 
disease.59 Tuberculosis is more likely in persons residing in 
or migrating from the developing world, while periodontal 
disease and other oral lesions due to the use of antiretroviral 
drugs seem to be most commonly reported in individuals in 
the developed world.60-62
Fungal Infections
Oral Candidosis
Candida albicans is the predominant yeast that 
colonizes the oral cavity of both healthy subjects and 
HIV-infected individuals in the developed and developing 
world.63 However, oral pseudomembranous candidosis 
(Figure 1) still remains the most common fungal infection 
of HIV disease; it has been associated with more frequent 
progression of HIV to AIDS and has been also used as a 
clinical marker to define the severity of HIV infection,64 
with pseudomembranous candidosis usually followed by 
erythematous candidosis. 
Candidal infection has been reported in adults, with 
a prevalence varying from 1.5 to 56%,65 with the higher 
prevalence rates in the developing world.65 The wide 
variability in the prevalence of oral candidosis may be 
attributed to a variety of factors including the socio-
demographic and clinical characteristics of the study group 
and the diagnostic methods employed.47 Pseudomembraneous 
candidosis (PC) is the most common clinical presentation 
of all candidal infections (ranging from 55.8 to 69.7%), 
followed by erythematous candidosis (EC) (25.7–50%), 
angular cheilitis (13.7–27.1%), and hyperplastic candidosis 
(0–1.7%).66,67 
Among children in the developed and developing world, 
rates of oral candidosis have been described as varying from 
22.5 to 83.3%.68 PC infection seems to be the most prevalent 
form in children69 followed by EC,70 and then angular 
Table 3 - Classification of oral manifestations of pediatric HIV disease
Group 1
lesions commonly associated with pediatric 
HIV infection
Group 2
lesions less commonly associated with 
pediatric HIV infection
Group 3
lesions strongly associated with HIV infection 
but rare in children
Candidosis
• Erythematous
• Pseudomembranous
• Angular cheilitis
Seborrhoeic dermatitis Neoplasms
• Kaposi’s sarcoma
• Non-Hodgkin’s lymphoma
Herpes simplex virus infection Bacterial infections of oral tissues
• Necrotizing (ulcerative) stomatitis
Oral hairy leukoplakia
Linear gingival erythema Periodontal diseases
• Necrotizing (ulcerative) gingivitis
• Necrotizing (ulcerative) periodontitis
Tuberculosis-related ulcers
Parotid enlargement Viral infections
• Cytomegalovirus
• Human papilloma virus
• Molluscum contagiosum
• Varicella–zoster virus
   ♦ Herpes zoster
   ♦ Varicella
Recurrent aphthous ulcers
• Minor
• Major
• Herpetiform
Xerostomia
Figure 1 - Severe pseudomembranous candidosis (Thrush) in HIV disease
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cheilitis as the third most prevalent.71 However, EC has been 
occasionally reported to be more prevalent than PC.72
The improvement in the immune system of patients 
receiving HAART may explain the reduction in the 
prevalence of this opportunistic infection in these groups of 
HIV-infected individuals. The frequency of oral candidosis 
usually correlates with a falling CD4+ T lymphocyte count 
and a rising HIV viral load.73 
Other factors that have been implicated in the 
predisposition of HIV patients to oral candidal infection are 
age under 35 years, injection drug use, and smoking more 
than 20 cigarettes a day.47 In contrast, some recent studies 
have not revealed any specific features that may predispose 
these patients to oral candidosis.74
Viral Infections
Oral hairy leukoplakia
Oral hairy leukoplakia (OHL) is a clinical manifestation 
of Epstein-Barr virus (EBV) infection almost exclusively 
found in patients with untreated advanced HIV disease 
and typically occurs on the lateral border of the tongue 
of HIV–infected individuals and other groups of 
immunocompromised individuals (Figure 2).75 The 
prevalence of OHL in recent studies of HIV-infected adults 
varies from 0.42 to 38% in both developed and developing 
countries.76-78 The increased prevalence of OHL might be 
related to a higher exposure to EBV,79 a lower CD4+ count, 
and a higher HIV viral load.80
Because OHL is asymptomatic and has no malignant 
potential, it rarely requires treatment. Nevertheless, 
acyclovir, and more recently valacyclovir, has been used for 
the treatment of OHL; unfortunately, acyclovir resistance 
can prevent the clinical resolution of OHL.81 As discussed 
previously, most but not all, relevant studies have observed 
that the frequency of OHL falls with HAART, thus further 
adding to the rationale that there is little if any need for 
active intervention in OHL.82
Oral Kaposi’s sarcoma
Kaposi’s sarcoma (KS) is a malignant, multifocal 
systemic disease that originates from the vascular 
endothelium and has a variable clinical course. KS is caused 
by human herpes virus 8 (HHV-8), which is transmitted 
sexually or via blood or saliva.83 The most frequently 
involved site is the skin, but mucous membranes, the 
lymphatic system, and viscera, in particular the lung and 
gastrointestinal tract, can also be involved.84 In patients with 
HIV disease, KS usually arises when the CD4+ T cell count 
is less than 200.85 
The prevalence of oral Kaposi’s sarcoma of the mouth 
varies from 0 to 12% in Africa and 0 to 38% in US and 
Europe. However, differences in the frequency of both oral 
and non-oral KS in HIV disease between the developed 
and developing world are likely to exist.86 In the developed 
world, the incidence of HIV-related KS began to decline 
from 25.6 cases per 1000 person-years (95% confidence 
interval [CI], 21.8-29.9) in the early 1990s to an average 
incidence of 7.5 per 1000 person-years (95% CI, 3.4-16.7) 
in 1996 and 199787 before HAART became available; this 
trend became more pronounced thereafter. In contrast, the 
prevalence of KS has risen alarmingly during this same time 
period in Africa.88 Since the advent of AIDS, KS has become 
more frequent in both genders, and the male to female ratio 
has changed from 19:1 to 1.7:1, particularly in East Africa. 
Recently, the high prevalence of oral KS was demonstrated 
by the observation that 18.6% of a group of HIV-infected 
patients in Zimbabwe and from 6 to 14% of another group 
of patients in the same region had oral KS.89 
Oral KS manifests as red to purple macules, papules, or 
nodules that may ulcerate and cause local tissue destruction 
(Figure 3).90 The palate and gingivae are the most commonly 
affected intraoral sites. In HIV disease, the oral cavity is 
commonly affected and is the first clinical site of KS in 20% 
of cases, while it occurs concomitantly with skin and visceral 
involvement in up to 70% of patients.92
At present, there is no preventive vaccine or antiviral 
agent for AIDS-related KS. Treatment is thus directed 
towards the elimination or at least reduction of cosmetically 
unacceptable lesions, the reduction of painful or unsightly 
edema or lymphadenopathy, as well as the relief of symptoms 
caused by visceral involvement.93 Local therapy may be 
effective for limited disease, but systemic therapy is required 
for disseminated KS. ART is useful in the management 
of HIV-related KS because it reduces the HIV viral load 
Figure 2 - Oral hairy leukoplakia – this finding can also be a feature of 
iatrogenic immunosuppression
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and raises the CD4+ T cell count, both of which indirectly 
contribute to the pathogenesis of KS.90 Older approaches 
for oral KS have included local radiation,93 laser therapy,94 
surgical excision, and cytotoxic therapy with vinca alkaloids 
(vinblastine, vincristine and vinorelbine) and bleomycin.95 
However, only five agents are currently approved by the FDA 
for the treatment of KS: alitretinoin gel for topical therapy 
and liposomal daunorubicin and oloxorubucin, paclitaxel, and 
interferon-alpha for systemic therapy.91,96 
Human Papillomavirus (HPV)
The reported increased prevalence of oral condylomas 
since the widespread administration of HAART suggests 
that a drug or combination of drugs used to treat HIV may 
be a risk factor for oral HPV infection.97 However, HPV 
infection has taken on much greater significance in recent 
years because the frequency of HPV infection has increased 
in groups examined following the introduction of HAART 
and especially because this virus may be of etiological 
significance in the development of oral squamous cell 
carcinoma (OSCC) [reviewed in detail elsewhere].98
HIV-infected individuals may be more likely to carry 
HPV in the mouth than immunocompetent individuals are 
(25.3 vs. 7.6%, respectively). They are also more likely to 
be infected by more than one HPV genotype (5.8 vs. 1.5%) 
and carry a high-risk genotype, such as HPV-16. Oral warts 
are uncommon in immunocompetent individuals but oral 
mucosal abnormalities such as papillomas are more likely 
to arise in those HPV-infected individuals with concomitant 
HIV disease.97 Oral HPV infection (both the carriage 
and/or clinical presentation) seems to be associated with 
male gender, HSV-2 seropositivity, and older age in HIV-
seronegative individuals. In HIV-infected populations, the 
risk factors for oral HPV infection still include male sex and 
HSV-2 serostatus, but the strongest association is with oral-
genital contact.99
The etiology of the high prevalence of oral HPV 
infection in HIV-infected individuals is unclear. It is possible 
that HIV-infected individuals exhibiting high-risk sexual 
practices frequently acquire oral HPV infection due to 
multiple exposures simply as a side effect of these high-risk 
practices. Alternatively, the high rates of HPV detection 
could be due to increased HPV replication and/or persistence 
rather than increased HPV acquisition. If persistence of oral 
HPV leads to HPV-related disease, as it does in the genital 
tract, increased persistence of HPV could also explain 
the increased prevalence of oral warts in HAART-treated 
HIV-positive individuals.100 It is also possible that the 
individuals who are placed on HAART have already been 
immunosuppressed long enough to surpass some critical 
threshold for developing HPV-related disease that cannot be 
then reversed with therapy.101
Gingival and Periodontal Diseases
Gingivitis and Periodontitis
Gingival and periodontal disease is common in HIV 
infection, particularly in individuals residing in or who 
have migrated from the developing world. The gingival and 
periodontal diseases associated with HIV include linear 
gingival erythema, NUG (Figure 4), NUP, and necrotizing 
stomatitis.102
Figure 3 - Kaposi’s sarcoma of the right buccal vestibule in an undiagnosed 
HIV-infected patient
Figure 4 - Necrotizing gingivitis in HIV disease
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Nevertheless, the most common gingival and periodontal 
features of HIV-infected persons are plaque related to 
gingivitis and chronic periodontitis, similar to that found 
in non-HIV-infected individuals. “Chronic” periodontal 
disease has been described to be more common and/or more 
aggressive in HIV-infected patients.103
The possible occurrence of HIV-specific periodontal 
disease has been observed in some but not all groups of 
HIV-infected patients, suggesting that HIV infection alone 
does not predispose patients to pocketing, attachment 
loss, or bleeding on probing.104 The reported prevalence of 
HIV-related gingival and periodontal disease (excluding 
opportunistic infections and malignancy) varies from 0 to 
47% in adults105 and from 0 to 20% in children; NUG and 
NUP are less prevalent, varying from 2.2 to 5%.106 Although 
aspects of HIV-induced immunosuppression have been 
proposed as the likely cause of HIV-related gingival and 
periodontal disease, HIV-infected patients often have other 
relevant risk factors, such as tobacco smoking and poor oral 
hygiene, and these factors alone can explain the increased 
prevalence of the disease.107
HIV-related salivary gland disease 
Salivary gland enlargement
HIV-associated salivary gland disease (HIV-SGD) is 
characterized by salivary gland swelling in one or both 
parotid glands with or without xerostomia.75 In some 
patients, salivary gland enlargement may be the first clinical 
manifestation of HIV infection. Inflammatory/infectious 
conditions are the second most common group of salivary 
gland disorders in HIV disease, followed by neoplastic 
lesions.108
Salivary gland enlargement occurs in approximately 3 
to 0% of adult patients infected with HIV, with a higher 
frequency in children, and it may be the first clinical 
manifestation of HIV. The swelling arises as a consequence 
of a variety of etiologies, including reactive/inflammatory 
conditions, infections, and neoplasms.109
Typically, the parotid gland is affected, and the swelling 
is bilateral, sometimes cystic, and seen in association with 
generalized lymphadenopathy, persistent circulating CD8+ 
lymphocytosis and diffuse visceral CD8+ lymphocytic 
infiltration. This symptom complex is termed diffuse 
infiltrative (CD8) lymphocytosis syndrome (DILS).110,111
In other cases, the swelling can be caused by benign 
parotid hypertrophy or cystic benign lymphoepithelial 
lesions (BLLs). These cysts may originate from an HIV-
related reactive lymphoproliferation of glandular epithelium 
trapped in normal intraparotid lymph nodes remaining from 
embryologic development or from a ductal obstruction of 
lymphoid proliferation leading to ductal dilatation.112
Inflammatory or infectious conditions are the second 
most common group of salivary gland disorders in HIV 
disease, followed by neoplastic lesions. Indeed, HIV-
infected patients have a high incidence of salivary NHL and 
secondary malignant neoplasms (e.g., Kaposi’s sarcoma) 
accounting for 10% of malignant salivary gland neoplasms 
in HIV disease.108
Xerostomia is a common symptom in HIV-infected 
individuals, and it has many potential causes. For example, it 
may accompany salivary gland enlargement in DILS,113 and 
it has also been reported to occur with HAART particularly 
some of the NRTIs and PIs.114 Antiretroviral agents such as 
lamivudine, didanosine (DDI) and the protease inhibitors can 
cause reduced salivary output. In addition, the long-term use 
of other non-HIV-related medications, such as many classes 
of antidepressants, can also lead to oral dryness.115
Treatment of salivary gland enlargement in HIV disease 
remains non-specific. While the frequency of HIV-SGD 
may increase with HAART, it occasionally resolves with 
HAART. Superficial parotidectomy has been advocated 
to alleviate the HIV-associated parotid swelling, but its 
application may be limited because of associated morbidity. 
Aspiration of cystic lesions can be of some transient 
benefit, and injections of tetracycline and doxycycline 
have minimal success due the presence of multiple cysts.116 
Benign parotid hypertrophy in HIV disease can be treated 
with external radiation therapy (24 Gy in 1.5 Gy daily 
fractions), with significant improvements in cosmetic 
control and long-term results.117
Figure 5 - Necrotic oral mucosal ulceration, possibly associated with CMV 
in severe HIV disease
467
CLINICS 2009;64(5):459-70 Oral complications of HIV disease
Leão JC et al.
Xerostomia
In general dental practice, many patients complain of 
xerostomia, typically secondary to drug therapy (particularly 
antidepressants and anxiolytics)118 but sometimes a sign 
of Sjogren’s syndrome.119 However, if a patient is known 
to have HIV disease, the xerostomia likely reflects HIV 
salivary gland disease or is an adverse side effect of ART.120 
All patients with xerostomia regardless of HIV serostatus 
must be given appropriate advice regarding the increased 
risk of caries (particularly cervical and root caries) and 
gingival inflammation. In addition, salivary substitutes and 
sialogogues may lessen the symptoms of xerostomia.121 
Neoplastic tumors
Non-Hodgkin’s lymphoma
Non-Hodgkin’s lymphoma (NHL) is the second most 
common HIV-associated tumor. As with KS, the frequency of 
this tumor has fallen with the introduction of ART; however, 
it is still a very common tumor of HIV-infected individuals 
in the developing world.122
A variety of NHLs can arise in the mouth in HIV disease; 
in fact, a rare type called plasmablastic lymphoma seems 
to nearly always arise exclusively in the mouth.123 The oral 
manifestations of NHL include soft tissue masses with or 
without ulceration and tissue necrosis, usually involving the 
gingival, palatal, and alveolar mucosa. The optimal treatment 
for HIV-associated NHL remains unclear. However, oral 
NHL management primarily entails systemic therapy124 with 
intensive high-dose chemotherapy and autologous stem cell 
transplantation; this latter treatment has resulted in sustained 
complete remissions in selected patients with recurrent 
chemosensitive disease.125
DENTAL CONSIDERATIONS FOR PEDIATRIC HIV 
PATIENTS
The oral manifestations of HIV infection in children 
are generally similar to those in adults, but there are some 
differences particularly with regards to caries and possibly 
the eruption times of teeth. HIV-infected children may 
be more vulnerable to dental caries, affecting both the 
deciduous and permanent dentition, than healthy subjects. 
However, the caries in HIV-infected children appear to be 
largely similar to those in other chronically sick children of 
comparable age.126 
Children with HIV disease may exhibit a different 
decay pattern than healthy children, possibly related to 
HIV-associated xerostomia.127,128 Part of the increase in 
caries in HIV-infected children may be attributed to the high 
carbohydrate and sugar intake required to prevent or treat 
any failure to thrive and to the ingestion of sucrose-based 
medications (particularly antibiotics and antifungals, but also 
antiretrovirals such as zidovudine.)129
In the developing world, poverty and lack of fluoride 
supplements may also contribute to an increased risk of 
dental caries in children with HIV disease.130 Both delayed 
and accelerated eruption of permanent teeth and over-
retention of primary teeth have been observed in some HIV-
infected children.130 The accelerated eruption pattern may 
be related to concurrent or previous dental and periodontal 
disease, but the exact cause of delayed eruption of teeth is 
unknown; the poor general health status of some children, 
particularly when there is malnutrition, may be an important 
co-factor.72
CONCLUSIONS
An understanding of the immunopathogenesis of HIV 
infection is a major prerequisite for rationally improving 
therapeutic strategies and developing immunotherapeutics 
and prophylactic vaccines. A better understanding of the oral 
manifestations of HIV/AIDS in both adults and children has 
implications for all dental health care workers in the world. 
We must assume that it is almost impossible to recognize 
if patients have, or are liable to have, HIV infection, and 
this knowledge must be reflected in the maintenance 
and continued updating of infection control policies in 
clinical practice. For that reason, it is necessary to integrate 
continuous and careful medical care of oral health as a part 
of the treatment for people with HIV/AIDS. The prevention, 
diagnosis, treatment, and control of these oral manifestations 
should be part of the objectives of every dental health 
professional; these professionals should hereafter also be 
informed about the relationship between immunological 
markers and the appearance of oral lesions. Key elements of 
the response to the HIV/AIDS epidemic include the support 
of the World Universal Public Health System, the provision 
of universal access to highly active antiretroviral therapy, and 
the creation of harm reduction projects that are politically 
and financially supported by federal governments. 
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